Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Japanese Pharma Companies Start Voluntary Recall Of Heparin

This article was originally published in PharmAsia News

Executive Summary

Japan's Ministry of Health, Labor and Welfare announced that Osaka-based Fuso Pharmaceutical, Tokyo-based Terumo Corp. and Tokushima-based Otsuka Pharmaceutical have begun recalling 17 heparin products. American drug maker Baxter Healthcare's heparin has been linked to severe side effects, including 21 deaths. The three Japanese companies use the same active ingredient for heparin as Baxter, which is imported from American company Scientific Protein Laboratories and made from materials in China. In Japan, 70 percent to 80 percent of the 270,000 dialysis patients use heparin, and Fuso and Otsuka products combined account for 50 percent of the heparin market. (Click here for more - Japanese language

Related Content

Japan Scrambles to Recall SPL-made Heparin



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts